Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 2
1997 1
1998 1
1999 2
2000 5
2002 1
2006 1
2008 2
2010 2
2011 1
2012 3
2013 3
2014 2
2015 3
2016 1
2017 3
2018 10
2019 8
2020 7
2021 9
2022 4
2023 10
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Jürgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Carinelli S, Provencher D, Hanzen C, Lutgens LCHW, Smit VTHBM, Singh N, Do V, D'Amico R, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL; PORTEC study group. de Boer SM, et al. Lancet Oncol. 2018 Mar;19(3):295-309. doi: 10.1016/S1470-2045(18)30079-2. Epub 2018 Feb 12. Lancet Oncol. 2018. PMID: 29449189 Free PMC article. Clinical Trial.
Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy.
Wortman BG, Creutzberg CL, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LCHW, van der Steen-Banasik EM, Mens JWM, Slot A, Kroese MCS, van Triest B, Nijman HW, Stelloo E, Bosse T, de Boer SM, van Putten WLJ, Smit VTHBM, Nout RA; PORTEC Study Group. Wortman BG, et al. Among authors: van triest b. Br J Cancer. 2018 Oct;119(9):1067-1074. doi: 10.1038/s41416-018-0310-8. Epub 2018 Oct 25. Br J Cancer. 2018. PMID: 30356126 Free PMC article. Clinical Trial.
Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer.
Horeweg N, Nout RA, Jürgenliemk-Schulz IM, Lutgens LCHW, Jobsen JJ, Haverkort MAD, Mens JWM, Slot A, Wortman BG, de Boer SM, Stelloo E, Verhoeven-Adema KW, Putter H, Smit VTHBM, Bosse T, Creutzberg CL; PORTEC Study Group. Horeweg N, et al. J Clin Oncol. 2023 Sep 20;41(27):4369-4380. doi: 10.1200/JCO.23.00062. Epub 2023 Jul 24. J Clin Oncol. 2023. PMID: 37487144 Free PMC article.
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.
de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, D'Amico R, Fyles A, Baron MH, Jürgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Gribaudo S, Provencher D, Hanzen C, Kruitwagen RF, Smit VTHBM, Singh N, Do V, Lissoni A, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL; PORTEC Study Group. de Boer SM, et al. Lancet Oncol. 2019 Sep;20(9):1273-1285. doi: 10.1016/S1470-2045(19)30395-X. Epub 2019 Jul 22. Lancet Oncol. 2019. PMID: 31345626 Free PMC article. Clinical Trial.
Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial.
Nout RA, Smit VT, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Mens JW, Slot A, Kroese MC, van Bunningen BN, Ansink AC, van Putten WL, Creutzberg CL; PORTEC Study Group. Nout RA, et al. Lancet. 2010 Mar 6;375(9717):816-23. doi: 10.1016/S0140-6736(09)62163-2. Lancet. 2010. PMID: 20206777 Clinical Trial.
Imaging predictors of treatment outcomes in rectal cancer: An overview.
Mahadevan LS, Zhong J, Venkatesulu B, Kaur H, Bhide S, Minsky B, Chu W, Intven M, van der Heide UA, van Triest B, Krishnan S, Hall WA. Mahadevan LS, et al. Among authors: van triest b. Crit Rev Oncol Hematol. 2018 Sep;129:153-162. doi: 10.1016/j.critrevonc.2018.06.009. Epub 2018 Jun 20. Crit Rev Oncol Hematol. 2018. PMID: 30097234 Review.
Thymidylate synthase and drug resistance.
Peters GJ, van der Wilt CL, van Triest B, Codacci-Pisanelli G, Johnston PG, van Groeningen CJ, Pinedo HM. Peters GJ, et al. Among authors: van triest b. Eur J Cancer. 1995 Jul-Aug;31A(7-8):1299-305. doi: 10.1016/0959-8049(95)00172-f. Eur J Cancer. 1995. PMID: 7577040 Free article. Review.
75 results